key: cord-0971173-m0xhxqhn authors: Arabi, Y. M.; Vishwakarma, R. K.; Al-Dorzi, H. M.; Al Qasim, E.; Abdukahil, S. A.; Al-Rabeeah, F. Q.; Al Ghamdi, H.; Al Ghamdi, E.; Group, SCREEN Trial title: Statistical Analysis Plan for the Stepped-wedge Cluster Randomized Controlled Trial of Electronic Early Notification of Sepsis in Hospitalized Ward Patients (SCREEN): a study protocol for a stepped-wedge cluster randomized controlled trial date: 2021-05-25 journal: nan DOI: 10.1101/2021.05.23.21257663 sha: fc92f4c6dd72ede27ea9e4225ffaa3a4169effb3 doc_id: 971173 cord_uid: m0xhxqhn Abstract Background It is unclear whether screening for sepsis using an electronic alert in hospitalized ward patients improves outcomes. The objective of the Stepped-wedge Cluster Randomized Controlled Trial of Electronic Early Notification of Sepsis in Hospitalized Ward Patients (SCREEN) is to examine the effect of electronic screening for sepsis compared to no screening among hospitalized ward patients on all-cause 90-day hospital mortality. Methods This study is designed as a stepped-wedge cluster randomized controlled trial. A sepsis e-alert was developed in the electronic medical record (EMR), with the feature of being active (visible to treating team) or masked (inactive in EMR frontend for the treating team but active in the backend of the EMR). Forty-five hospital wards in 5 hospitals are randomized to active sepsis e-alert versus masked sepsis e-alert on 2-month sequences, with 5 wards in each sequence totaling 10 sequences. The primary endpoint is in-hospital mortality by 90 days. All data are extracted from EMR. Discussion The SCREEN trial provides an opportunity for a novel trial design and analysis of routinely collected and entered data to evaluate the effectiveness of an intervention (sepsis alert) for a common medical problem (sepsis in ward patients). In this statistical analysis plan, we outline details of the planned analyses in advance of trial completion. Prior specification of the statistical methods and outcomes analysis will facilitate unbiased analyses of these important clinical data. Trial registration ClinicalTrials.gov NCT04078594. Registered on September 6, 2019, https://clinicaltrials.gov/ct2/show/NCT04078594 Keywords Sepsis, Alert, Screening, qSOFA, mortality, electronic medical records It is unclear whether screening for sepsis using an electronic alert in hospitalized ward patients improves outcomes. The objective of the Stepped-wedge Cluster Randomized Controlled Trial of Electronic Early Notification of Sepsis in Hospitalized Ward Patients (SCREEN) is to examine the effect of electronic screening for sepsis compared to no screening among hospitalized ward patients on all-cause 90-day hospital mortality. This study is designed as a stepped-wedge cluster randomized controlled trial. A sepsis e-alert was developed in the electronic medical record (EMR), with the feature of being active (visible to treating team) or masked (inactive in EMR frontend for the treating team but active in the backend of the EMR). Forty-five hospital wards in 5 hospitals are randomized to active sepsis ealert versus masked sepsis e-alert on 2-month sequences, with 5 wards in each sequence totaling 10 sequences. The primary endpoint is in-hospital mortality by 90 days. All data are extracted from EMR. The SCREEN trial provides an opportunity for a novel trial design and analysis of routinely collected and entered data to evaluate the effectiveness of an intervention (sepsis alert) for a common medical problem (sepsis in ward patients). In this statistical analysis plan, we outline details of the planned analyses in advance of trial completion. Prior specification of the statistical methods and outcomes analysis will facilitate unbiased analyses of these important clinical data. Sepsis is a major cause of morbidity and mortality among hospitalized patients. Sepsis outcome is greatly dependent on the time-sensitive administration of appropriate antimicrobials, fluid resuscitation, and source control. (1, 2) Screening for sepsis using an electronic alert in hospitalized patients may improves outcomes by early sepsis recognition and timely implementation of appropriate care processes. However, the evidence for such an intervention is modest,(3) and a randomized controlled trial is needed to measure its true effect. Notification of Sepsis in Hospitalized Ward Patients (SCREEN) is to examine the effect of electronic screening for sepsis compared to no screening among hospitalized ward patients on all-cause 90-day hospital mortality. The study protocol has been submitted for publication. The electronic screening for sepsis is based on the quick Sequential Organ Failure Assessment qSOFA. (4) In this manuscript we describe statistical analysis plan (SAP) of the SCREEN trial. This SAP plan complies with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, and both the "Statistical principles for clinical trials E9" and "Structure and content of clinical study reports E3". (5, 6) The final study report will follow the CONSORT (Consolidated Standards of Reporting Trials) 2010 guidelines for reporting randomized controlled trials and the CONSORT extension for cluster randomized trials (CRTs). (7) (8) (9) This SAP identifies the procedures to be applied to the primary and secondary analyses for the entire trial cohort once trial data is complete. The SAP was finalized during trial implementation, and all analyses were prospectively defined. been generated every two weeks of the same data and shared with the teams in the active wards. The hospital administration and quality management department has been engaged in the process of feedback and of improving the response time to alerts. The medical management and assessment have been at the discretion of the treating team, and the project has adopted the 2016 Surviving Sepsis Campaign guidelines and the hour-1 bundle, but without any specific monitoring of bundle compliance. (10, 11) The study has been conducted in the 5 and Imam Abdulrahman Al Faisal Hospital -Dammam. A CONSORT diagram will be generated according to the CONSORT extension for cluster randomized trials (CRTs).(9); for each allocated sequence at each period, the number of clusters receiving intervention, the average cluster size, and its variance, and the number of clusters not receiving intervention will be presented ( Figure 1 ). The sample size for this stepped-wedge cluster-randomized design was calculated for 45 clusters with 10 time periods (1 baseline time period followed by 9 steps) using Power Analysis and Sample Size (PASS) software (PASS 15 Power Analysis and Sample Size Software (2017). NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass). At each of the 9 steps, 5 clusters (wards) switch from masked alert to active alert. Using historical data obtained from the development domain of the EM) for ward patients admitted from 01 July 2018 to 30 June 2019, we calculated a baseline hospital mortality rate of 3.13% by day 90. Based on the same dataset, 18.3% of eligible ward patients had the sepsis e-alert based on qSOFA criteria(4) with a hospital All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.23.21257663 doi: medRxiv preprint mortality of 8.16% compared to 2% in the non-sepsis alert patients. For sample size calculations, we made the following assumptions: A) the impact of intervention on mortality occurs only in patients who have the alert, B) Only half of patients with the alert have sepsis, C) 90% of deaths among the patients with the alert occurred among septic patients, D) early intervention resulting from the sepsis alert will reduce the hospital mortality by 50%, i.e. from 8.16% to 4.08% in patients with sepsis and would lead to an overall change in hospital mortality for the whole cohort from 3.13% to 2.46%, D) 90 % power using two-sided Wald Z-Test and significance level of 5% and, E) an intra-cluster correlation (ICC, a measure of the relatedness of cluster) of 0.22 as estimated from retrospective electronic database. As such, a reduction of mortality in hospital by 90 days by 0.67% (from 3.13% to 2.46%) requires a total sample size of 62550 subjects (average of 1390 subjects per cluster with an average of 139 subjects per cluster per time period). With all five hospitals combined, this is expected to require 20 months (2 months per time period). The intention-to-treat (ITT) cohort includes all eligible patients admitted to the eligible wards. A list of ward-level and patient-level eligibility criteria are outlined in the study protocol. (12) This population constitutes the patients who are subjected to sepsis screening by the sepsis alert system, whether they had an alert or not. The ITT analysis also implies that patients in the ITT cohort in the wards belonging to a particular randomization period will be analyzed in accordance with their planned randomization regardless of what happens during the trial. For example, if a ward was planned to have active alert during a period and for technical reasons that alert system was not operational, patients recruited in that ward during that period will be analyzed as receiving active alert. Although it is not anticipated that there will be wards who All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.23.21257663 doi: medRxiv preprint cross-over their study cohort (i.e., change from alert to non-alert, or vice versa), any instances will be documented. Patients who are transferred from one ward to another will be counted as part of the first ward. The primary analysis will be based on this population. This cohort represents the subset of patients who had the alert whether in the active wards or the masked wards. Baseline characteristics will be presented for the ITT and alert cohorts (Table S1) We will also report vital signs (systolic blood pressure, diastolic blood pressure, heart rate, temperature, and respiratory rate) as well as laboratory parameters (lactate, white blood cells, bilirubin, creatinine) and whether culture of blood, respiratory, urine or other body fluids (pleural, ascitic, CSF, joint) were obtained and whether treatments (intravenous fluids and antibiotics) were received at baseline. Definitions of these variables were outlined in the study protocol.(12) We will report the number of patients with at least one alert, and the number of alerts per patient, time to first alert and alert information criteria which led to alert trigger (Table S2 ). We will report vital signs in the 12 hours pre-alert (systolic blood pressure, diastolic blood pressure, heart rate, temperature, and respiratory rate) as well as laboratory parameters in the 12 hours pre-alert (lactate, white blood cells, bilirubin, creatinine) and whether culture of blood, 1 0 respiratory, urine or other body fluids (pleural, ascitic, CSF, joint) were obtained and whether treatments (intravenous fluids and antibiotics) were received in the 12 hours pre-alert. We will compare the following process measures between the two groups: A) percentage of patients with lactate reported 12 hours if not reported in the 12 hours before alert and highest lactate value reported in the 12 hours after the alert, B) percentage of patients with blood culture ordered in 12 hours if not performed in the 12 hours before alert, C) percentage of patients with respiratory, urine and body fluid cultures ordered in 12 hours if not performed in the 12 hours before alert, D) intravenous fluid administered in 12 hours after alert (yes, no), E) percentage of patients who were not on antibiotics in the 12 hours before alert and had new antibiotic administered within 3 and 12 hours of alert, F) post-alert systolic and diastolic blood pressure: (lowest value in the 12 hours after the alert) and heart and respiratory rate (highest value in the 12 hours after the alert) (Table S2) . The primary outcome is defined as all-cause mortality after enrollment in the trial within 90 days. Other outcomes include hospital length of stay (LOS) (ITT cohort and alert cohort), transfer to ICU within 90 days (ITT cohort and alert cohort) and 14 days of alert (alert cohort), ICU-free days in the first 90 days (ITT cohort and alert cohort), critical care response team (CCRT) activation within 90 days (ITT cohort and alert cohort) and 14 days of alert (alert cohort), cardiac arrest within 90 days (ITT cohort and alert cohort) and 14 days of alert (alert cohort), the need for mechanical ventilation, vasopressor therapy, incident renal replacement therapy within 90 days (all in ITT cohort and alert cohort) and 14 days of alert (alert cohort), antibiotic-free days and acquisition of multidrug resistant organisms within 90 days in both groups (ITT cohort and alert cohort) (Table S3 and S4). The primary outcome of all-cause hospital mortality by day 90 will be compared between patients who have been exposed to the intervention to those who have not yet been exposed to the intervention using a 2-level multilevel Poisson model with a log link and with an offset term to account for variation due to lengths of time to the no alert and alert periods (Table S3 ). We will include two-level random effects to account for nested clustering within the data, patients within wards, and wards within the hospitals in the study and one fixed effect term for each period. The model will be adjusted for following covariates: type of wards (medical, surgical, Oncology and mixed), age, baseline systolic blood pressure, baseline respiratory rate and Charlson comorbidity index. Results will be expressed as relative risk with 95% confidence interval (CI). The absolute risk difference and number needed to treat, if applicable, will be also reported. The primary outcome will be also analyzed in a similar fashion in the alert cohort. Categorical outcomes including ICU admission, critical care response team (CCRT) activation, cardiac arrest, the need for mechanical ventilation, vasopressor therapy, incident renal replacement therapy, acquisition of multidrug resistant organisms and Clostridium difficile infection will be compared between patients who have been exposed to the intervention to those who have not yet been exposed to the intervention using a 2-level multilevel mixed-effects logistic regression models (Table S3 & S4) . We will include two-level random effects to account for nested clustering within the data, patients within wards, and wards within the hospitals in the study and one fixed effect term for each period. The model will be adjusted for predictors as considered for primary outcome. Results will be expressed as relative risk with 95% CI. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.23.21257663 doi: medRxiv preprint Continuous outcomes including hospital length of stay (LOS), ICU-free days, and antibiotic-free days will be compared using a 2-level multilevel Poisson model with a log link and with an offset term to account for variation due to lengths of time to the no alert and alert periods (Table S3) . We will include two-level random effects to account for nested clustering within the data, patients within wards, and wards within the hospitals in the study and one fixed effect term for each period. The model will be adjusted for the same covariates as considered for primary outcome. The results will be expressed as beta estimates with 95% CI. We will use the same model to analyze the primary outcome of all-cause hospital mortality by day 90 across predefined subgroups (Table S6 ). The statistical model will be adjusted accordingly to fit the subgroup analyses. Results of test of interaction will be reported. As we are expecting missing observations at patient level, all missing data will be assessed and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Kaplan Meier curves will be constructed for all-cause hospital mortality by day 90 in the ITT cohort and the alert cohort and the p-value for log rank test will be reported. The subgroup analyses will be displayed as a forest plot. To adjust for multiple testing for secondary outcomes, we will use the False Discovery Rate (FDR) as described by Benjamini and Hochberg.(15) In this procedure all hypothesis tests will be sorted in an descending order based on their calculated p-value. All hypothesis tests below an index K will be rejected where K calculated as follows: where i =m, …, 1, m is the total number of tested hypotheses; q = 0.05. Statistical tests and their confidence intervals (CIs) will be calculated with two sided. The statistical significance level set will be at the 5% level. All analyses will be performed using SAS version 9.4. The SCREEN trial provides an opportunity for a novel trial design and analysis of routinely collected and entered data to evaluate the effectiveness of an intervention (sepsis alert) for a common medical problem (sepsis in ward patients). Stepped-wedge cluster randomized trial involves randomization of clusters to different sequences. This design is suitable for quality improvement projects. In the SCREEN trial, it allows the assessment of the effect of sepsis alert by comparing the outcomes of patients in the 1 4 intervention and control cohorts as well as over time. (9) In addition, by having the masked alert, an additional comparison between patients with masked and active alerts will be performed. Our analysis plan highlights some potential trial limitations, in relation to the low event rate, which we have addressed by the large sample size. We will address multiplicity of secondary analyses by reporting the False Discovery Rate. Our sepsis alert which is based on qSOFA is generalizable in other healthcare settings, although there may be variations across different EMRs. The variability among clusters and over time are inherent issues with stepped-wedge cluster randomized trial, which we addressed in the statistical analysis model. The study has started in October 2019, and is anticipated to have complete implementation and follow up data by the end of October 2021. In this statistical analysis plan, we outline details of the planned analyses in advance of trial completion. Prior specification of the statistical methods and outcomes analysis will facilitate unbiased analyses of these important clinical data. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study was approved by the Institutional Review Board of the Ministry of National Guard -Health Affairs. Informed consent was waived because of the nature of the study. Not applicable. The datasets will be available from the corresponding author as per the regulations of King Abdullah International Medical Research Center (KAIMRC). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.23.21257663 doi: medRxiv preprint 1 7 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock Early goaldirected therapy in the treatment of severe sepsis and septic shock Diagnostic accuracy and effectiveness of automated electronic sepsis alert systems: a systematic review The third international consensus definitions for sepsis and septic shock (Sepsis-3) Many multicenter trials had few events per center, requiring analysis via random-effects models or GEEs Impact of patient position on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials explanation and elaboration: updated guidelines for reporting parallel group randomised trials statement: updated guidelines for reporting parallel group randomised trials Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive care medicine The surviving sepsis campaign bundle Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers Statistical Analysis with Missing Data Strategies to fit patternmixture models Controlling the false discovery rate: a practical and powerful approach to multiple testing All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.